Compare NTIC & CLNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTIC | CLNN |
|---|---|---|
| Founded | 1970 | 2012 |
| Country | United States | United States |
| Employees | N/A | 79 |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.1M | 73.7M |
| IPO Year | 1996 | N/A |
| Metric | NTIC | CLNN |
|---|---|---|
| Price | $8.08 | $6.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $33.00 |
| AVG Volume (30 Days) | 9.0K | ★ 87.3K |
| Earning Date | 04-09-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.49% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $84,234,474.00 | N/A |
| Revenue This Year | $11.40 | $17.64 |
| Revenue Next Year | $8.70 | $19,516.77 |
| P/E Ratio | $404.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.10 | $2.28 |
| 52 Week High | $10.03 | $13.50 |
| Indicator | NTIC | CLNN |
|---|---|---|
| Relative Strength Index (RSI) | 45.34 | 58.75 |
| Support Level | $7.34 | $5.59 |
| Resistance Level | $8.58 | $6.83 |
| Average True Range (ATR) | 0.33 | 0.58 |
| MACD | 0.02 | 0.08 |
| Stochastic Oscillator | 26.00 | 81.28 |
Northern Technologies International Corp is a United States-based firm that develops and markets proprietary, environmentally beneficial products and services world wide either directly or through a network of joint ventures, distributors, and agents. It operates through two segments, which include ZERUST products and services and Nature-Tec products. Its main business is providing corrosion prevention solutions that are marketed under the ZERUST brand. The company also sells a portfolio of bio-based and biodegradable (compostable) polymer resin compounds and finished products marketed under the Nature-Tec brand. The ZERUST brand generates a vast majority of the revenue for the company. The company generates the majority of its revenue in the United States.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.